Latest News

How this gene-agnostic optogenetic approach could fill a critical gap for advanced inherited retinal degeneration.

Border zone lifetime gradient correlated with growth rate over 5 years

Varicella vaccine drove the largest risk reduction in a 5-vaccine, multi-million-patient analysis

Ultra-widefield imaging reveals early retinal risk in pediatric patients.

Three cases illustrate how next-generation anti-VEGF agents are extending treatment intervals and improving durability across retinal vascular disease.

SOL-1 results show intravitreal axitinib hydrogel delivered superior vision maintenance and anatomic outcomes through 52 weeks.

New IGF-1R antibody Lumvoa receives FDA nod for active and chronic thyroid eye disease, offering rapid proptosis relief and diplopia improvement.

A randomized trial found that 8 weeks of daily use of the Calm Health app significantly improved mental health outcomes in adults with non-infectious uveitis.

A prospective pilot study finds focal photopic microperimetry may detect cone-mediated losses that lesion size and visual acuity do not reflect.

StemSight secures new patents for scalable induced pluripotent stem cells-derived limbal stem cells, boosting STE-101’s path to off-the-shelf limbal stem cell deficiency therapy and upcoming Series A.

Learn how FDA’s interchangeable ranibizumab biosimilar may streamline injections, cut costs, and guide safe switching for retina patients.

A retrospective study identifies thin choroid as the key factor behind ungradable ultrawidefield green-light fundus autofluorescence images in geographic atrophy.

Alkeus Pharmaceuticals has dosed the first participant in the phase 3 NORTHSTAR trial of oral gildeuretinol for Stargardt disease, a condition with no approved treatments.